DoW Parkinson’s, Investigator-Initiated Research Award
Dept. of Defense — CDMRP · Other Federal · HT942526PRPIIRA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $10M total
- DeadlineFinal application due date.
- Nov 6, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 5
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- Jun 18, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $10M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs. · Preliminary data are required. · Clinical trials are allowed.